Search
15 results for “methylenedioxymethamphetame”
-
-
https://pubmed.ncbi.nlm.nih.gov/38743292/ The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns (Baldo, et al, 2024) #mdma #fda #entactogens #psychedelic #psychedelics #psychedelicresearch #psychedelicassistedpsychotherapy #mdmaassistedtherapy Note: FDA has approved trials of MDMA for: #ptsd #socialanxiety (especially related to #autism) #alcoholusedisorder #eatingdisorders #asociality related to #schizophrenia #deathanxiety
-
https://pubmed.ncbi.nlm.nih.gov/38743292/ The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns (Baldo, et al, 2024) #mdma #fda #entactogens #psychedelic #psychedelics #psychedelicresearch #psychedelicassistedpsychotherapy #mdmaassistedtherapy Note: FDA has approved trials of MDMA for: #ptsd #socialanxiety (especially related to #autism) #alcoholusedisorder #eatingdisorders #asociality related to #schizophrenia #deathanxiety
-
https://pubmed.ncbi.nlm.nih.gov/38743292/ The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns (Baldo, et al, 2024) #mdma #fda #entactogens #psychedelic #psychedelics #psychedelicresearch #psychedelicassistedpsychotherapy #mdmaassistedtherapy Note: FDA has approved trials of MDMA for: #ptsd #socialanxiety (especially related to #autism) #alcoholusedisorder #eatingdisorders #asociality related to #schizophrenia #deathanxiety
-
https://pubmed.ncbi.nlm.nih.gov/38743292/ The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns (Baldo, et al, 2024) #mdma #fda #entactogens #psychedelic #psychedelics #psychedelicresearch #psychedelicassistedpsychotherapy #mdmaassistedtherapy Note: FDA has approved trials of MDMA for: #ptsd #socialanxiety (especially related to #autism) #alcoholusedisorder #eatingdisorders #asociality related to #schizophrenia #deathanxiety
-
https://pubmed.ncbi.nlm.nih.gov/38957734/ Hepatic injury and hepatic failure adverse events in 3,4-methylenedioxymethamphetamine users reported to the FDA Adverse Event Reporting System (Makunts, et al, 2024) #mdma #dili #liver #psychedelic #psychedelicresearch #faers #fda #psychedelics #mdmaassistedtherapy — finding in estimated 20 million, perhaps 1 case of liver damage from MDMA, increased risk with poly drug use.
-
https://pubmed.ncbi.nlm.nih.gov/38957734/ Hepatic injury and hepatic failure adverse events in 3,4-methylenedioxymethamphetamine users reported to the FDA Adverse Event Reporting System (Makunts, et al, 2024) #mdma #dili #liver #psychedelic #psychedelicresearch #faers #fda #psychedelics #mdmaassistedtherapy — finding in estimated 20 million, perhaps 1 case of liver damage from MDMA, increased risk with poly drug use.
-
https://pubmed.ncbi.nlm.nih.gov/38957734/ Hepatic injury and hepatic failure adverse events in 3,4-methylenedioxymethamphetamine users reported to the FDA Adverse Event Reporting System (Makunts, et al, 2024) #mdma #dili #liver #psychedelic #psychedelicresearch #faers #fda #psychedelics #mdmaassistedtherapy — finding in estimated 20 million, perhaps 1 case of liver damage from MDMA, increased risk with poly drug use.
-
https://pubmed.ncbi.nlm.nih.gov/38957734/ Hepatic injury and hepatic failure adverse events in 3,4-methylenedioxymethamphetamine users reported to the FDA Adverse Event Reporting System (Makunts, et al, 2024) #mdma #dili #liver #psychedelic #psychedelicresearch #faers #fda #psychedelics #mdmaassistedtherapy — finding in estimated 20 million, perhaps 1 case of liver damage from MDMA, increased risk with poly drug use.
-
https://www.bmj.com/content/386/bmj-2023-078607 Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis (Hsu, et al, 2024) — What a missed opportunity to test oral #ketamine as a control #psychedelic #psychedelics #psilocybin #lsd #ayahausca #depression #mentalhealth #psychedelicresearch #escitalopram #mdma
-
https://www.bmj.com/content/386/bmj-2023-078607 Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis (Hsu, et al, 2024) — What a missed opportunity to test oral #ketamine as a control #psychedelic #psychedelics #psilocybin #lsd #ayahausca #depression #mentalhealth #psychedelicresearch #escitalopram #mdma
-
https://www.bmj.com/content/386/bmj-2023-078607 Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis (Hsu, et al, 2024) — What a missed opportunity to test oral #ketamine as a control #psychedelic #psychedelics #psilocybin #lsd #ayahausca #depression #mentalhealth #psychedelicresearch #escitalopram #mdma
-
https://www.bmj.com/content/386/bmj-2023-078607 Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis (Hsu, et al, 2024) — What a missed opportunity to test oral #ketamine as a control #psychedelic #psychedelics #psilocybin #lsd #ayahausca #depression #mentalhealth #psychedelicresearch #escitalopram #mdma
-
https://www.bmj.com/content/386/bmj-2023-078607 Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis (Hsu, et al, 2024) — What a missed opportunity to test oral #ketamine as a control #psychedelic #psychedelics #psilocybin #lsd #ayahausca #depression #mentalhealth #psychedelicresearch #escitalopram #mdma
